← Back to Search

Educational Strategies for Extubation Outcomes (METEOR Trial)

N/A
Waitlist Available
Led By Timothy D Girard, MD, MSCI
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All adults treated with invasive mechanical ventilation >24 hours in participating ICUs
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

METEOR Trial Summary

This trial will compare four implementation strategies for ICU care: traditional online education, protocol-directed care, interprofessional education, and a combination of the two. They will test the hypotheses that interprofessional education is superior to traditional online education, and that the benefits of interprofessional education are increased when interprofessional education is paired with a clinical protocol. Additionally, they will test the hypothesis that preventive post-extubation NIV and preventive post-extubation HFNC are both superior to current clinical practice.

Who is the study for?
The METEOR Trial is for adults who have been on a ventilator for more than 24 hours in certain ICUs. There are no specific exclusion criteria, so it's open to all eligible patients meeting the inclusion condition.Check my eligibility
What is being tested?
This trial tests four strategies after extubation: traditional online education, protocol-directed care, interprofessional education, and a mix of both education and protocol. It aims to find out if special training or protocols improve patient outcomes compared to usual oxygen therapy.See study design
What are the potential side effects?
Since this trial involves educational and organizational interventions rather than medications, there are no direct side effects like those seen with drugs. However, different oxygen delivery methods may vary in comfort or effectiveness.

METEOR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was on a breathing machine for more than a day in the ICU.

METEOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
In-hospital mortality truncated at 60 days from intubation (primary clinical outcome)
Rate of use of post-extubation NIV or HFNC among eligible participants (primary implementation outcome)
Secondary outcome measures
28-day ventilator-free days (VFDs)
90-day survival
Duration of mechanical ventilation
+7 more

METEOR Trial Design

9Treatment groups
Active Control
Group I: Interprofessional education about post-extubation HFNCActive Control2 Interventions
During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
Group II: Interprofessional education plus clinical protocol about post-extubation HFNCActive Control3 Interventions
During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
Group III: Clinical protocol about post-extubation HFNCActive Control2 Interventions
During this period, ICU providers deploy a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
Group IV: Interprofessional education about risk-stratified post-extubation NIV/HFNCActive Control2 Interventions
During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
Group V: Clinical protocol about risk-stratified post-extubation NIV/HFNCActive Control2 Interventions
During this period, ICU providers deploy a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
Group VI: Interprofessional education plus clinical protocol about risk-stratified post-extubation NIV/HFNCActive Control3 Interventions
During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
Group VII: Online education about post-extubation HFNCActive Control2 Interventions
During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
Group VIII: Usual careActive Control1 Intervention
During this period, ICU providers receive no structured education about preventive, post-extubation respiratory support therapies
Group IX: Online education about risk-stratified post-extubation NIV/HFNCActive Control2 Interventions
During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,712 Previous Clinical Trials
16,329,611 Total Patients Enrolled
1 Trials studying Acute Respiratory Failure
1,328 Patients Enrolled for Acute Respiratory Failure
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,814 Previous Clinical Trials
47,274,075 Total Patients Enrolled
9 Trials studying Acute Respiratory Failure
20,188 Patients Enrolled for Acute Respiratory Failure
Timothy D Girard, MD, MSCIPrincipal InvestigatorUniversity of Pittsburgh
1 Previous Clinical Trials
1,328 Total Patients Enrolled
1 Trials studying Acute Respiratory Failure
1,328 Patients Enrolled for Acute Respiratory Failure

Media Library

Clinical protocol Clinical Trial Eligibility Overview. Trial Name: NCT05523479 — N/A
Acute Respiratory Failure Research Study Groups: Interprofessional education about post-extubation HFNC, Interprofessional education plus clinical protocol about post-extubation HFNC, Clinical protocol about post-extubation HFNC, Interprofessional education about risk-stratified post-extubation NIV/HFNC, Clinical protocol about risk-stratified post-extubation NIV/HFNC, Interprofessional education plus clinical protocol about risk-stratified post-extubation NIV/HFNC, Online education about post-extubation HFNC, Usual care, Online education about risk-stratified post-extubation NIV/HFNC
Acute Respiratory Failure Clinical Trial 2023: Clinical protocol Highlights & Side Effects. Trial Name: NCT05523479 — N/A
Clinical protocol 2023 Treatment Timeline for Medical Study. Trial Name: NCT05523479 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research program currently enrolling participants?

"Clinicaltrials.gov records indicate that this medical research is not actively enrolling candidates at the moment, despite being initially posted in January 1st 2023 and most recently updated on November 7th 2022. Despite this, 179 other clinical trials are requesting participants right now."

Answered by AI

What is the primary objective of this experiment?

"The main goal of this trial, which is to be evaluated over a period of 60 days following the initiation of invasive mechanical ventilation, is to assess the rate of post-extubation noninvasive ventilatory or high flow nasal cannula usage among eligible participants. Secondary endpoints include 28-day ventilator free periods (VFDs) from intubation till 28 days later without reintubation for at least 48 hours; duration between initiating invasive mechanical ventilation and successful extubation with no need for reintubations again within 48 hours; along with hospital stay length ranging from initial intubation until successful discharge"

Answered by AI
Recent research and studies
~9975 spots leftby Nov 2025